Login to Your Account



Q3 earnings reports weigh on Abbvie and Amgen, keep Biomarin and Seagen steady

By Michael Fitzhugh
Staff Writer

Friday, October 28, 2016

Worries over slowing global sales of Abbvie Inc.'s largest product, Humira, and fears about the outlook for Amgen Inc.'s Enbrel dimmed the shine on shares of both companies by Friday's close.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription